SEC Filings
ADAR1 Funds Hold 8.7% Of Fulcrum Therapeutics Without Seeking To Influence Control
The private funds own 6,648,027 common shares in the rare-disease drug developer, with voting power shared by their adviser and its manager.
Fulcrum Therapeutics (FULC) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The private funds own 6,648,027 common shares in the rare-disease drug developer, with voting power shared by their adviser and its manager.
Deals
The buyer's payment is expected to count toward Fulcrum's net cash under its proposed merger with Slate Medicines.
Deals
Fulcrum's amended merger filing with Slate Medicines shows a $270.5 million dividend and a December 3 shareholder vote.
Deals
The S-4/A for the pending Slate Medicines merger leaves the reverse split ratio blank and sets an estimated exchange ratio of about 24.8186.
Deals
An amended S-4 shows Slate holders and new investors taking the rest, with a dividend of about $270 million paid before closing.